China Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market Activity

Rhea-AI Summary

China Pharma (NYSE American: CPHI) reported that NYSE American contacted the company after unusual trading in its common stock on May 12–13, 2026. China Pharma stated it is not aware of any material nonpublic information or undisclosed business developments that would explain the recent market activity.

News Market Reaction – CPHI

+24.45%

28 alerts

+24.45% Session close to close

+62.2% Peak Tracked

-4.4% Trough Tracked

$59.16M Market Cap

0.8x Rel. Volume

In the May 14 session, CPHI gained 24.45%, reflecting a significant positive market reaction. Argus tracked a peak move of +62.2% during that session. Argus tracked a trough of -4.4% from its starting point during tracking. Our momentum scanner triggered 28 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +24.4% in the session following this news. A strong positive reaction aligns with h...

Analysis

The stock surged +24.4% in the session following this news. A strong positive reaction aligns with heightened trading interest despite the company stating it knew of no undisclosed developments behind recent activity. The move came with volume of 720,793, only slightly above the 20-day average, and the stock still sat well below its $2.5977 52-week high and under its $1.25 200-day MA, indicating prior technical weakness could influence how durable such spikes became.

Key Terms

unusual market activity, material nonpublic information

2 terms

unusual market activity technical

"in view of the unusual market activity in the common stock of China Pharma"

A pattern of trading in a stock that departs sharply from its recent norms — for example sudden large swings in price or volume — suggesting something unusual is driving demand or supply. Like a sudden crowd forming outside a shop, it can signal new information, investor excitement, or potential manipulation, so investors pay attention as a prompt to investigate, reassess risk, or consider adjusting positions.

material nonpublic information regulatory

"it is not aware of any material nonpublic information or business developments"

Nonpublic information is specific, important news about a company or its securities that has not been shared with the general public and that a reasonable investor would consider likely to affect the company’s stock price. It matters to investors because using or sharing that information to buy or sell securities can give an unfair advantage and is often illegal; think of it like having the exam answers before a test, which undermines a fair playing field for everyone.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HAIKOU, China, May 14, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced that, in view of the unusual market activity in the common stock of China Pharma on May 12 and 13, the NYSE American has contacted the Company in accordance with its usual practice. The Company stated that, while its policy generally is not to comment on unusual market activity, it is not aware of any material nonpublic information or business developments that have not been publicly disclosed that would account for the recent trading activity.

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high-margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com. The Company routinely posts important information on its website.

Safe Harbor Statement 

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as the achievability of financial guidance, success of new product development, unanticipated changes in product demand, increased competition, downturns in the Chinese economy, uncompetitive levels of research and development, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations except as required by applicable law or regulation.

Contact:
China Pharma Holdings, Inc.                                  
Phone: +86-898-6681-1730 (China)                                         
Email: hps@chinapharmaholdings.com

View original content:https://www.prnewswire.com/news-releases/china-pharma-holdings-inc-states-it-knows-of-no-events-that-could-have-caused-unusual-market-activity-302772402.html

SOURCE China Pharma Holdings, Inc.

FAQ

What unusual market activity affected China Pharma (CPHI) stock in May 2026?

China Pharma common stock experienced unusual market activity on May 12 and 13, 2026. According to China Pharma, this prompted contact from NYSE American, which inquired about any relevant corporate developments or undisclosed information that might explain the trading in CPHI shares.

How did China Pharma (CPHI) respond to NYSE American about the May 2026 trading activity?

China Pharma stated it is not aware of any material nonpublic information explaining the unusual trading. According to China Pharma, there are no undisclosed business developments or corporate events that would reasonably account for the recent activity in its CPHI common stock.

Did China Pharma disclose any new material information after the May 12–13, 2026 activity in CPHI stock?

China Pharma said it knows of no material nonpublic information related to the trading. According to China Pharma, there are no new, undisclosed business developments that would justify or clarify the unusual market activity observed in its shares on those dates.

What is China Pharma’s policy on commenting about unusual market activity in CPHI shares?

China Pharma noted that its general policy is not to comment on unusual trading in its stock. According to China Pharma, the company made an exception to confirm it is unaware of any undisclosed material information tied to the recent CPHI market activity.

Should CPHI investors expect further announcements about the May 2026 trading activity?

China Pharma has only stated it knows of no undisclosed material information explaining the trading. According to China Pharma, there are no identified business developments behind the activity, and no additional specific updates were announced in connection with the May 12–13, 2026 events.